LLY

988.07

+2.29%↑

JNJ

193.84

+3.17%↑

ABBV

225.16

+3.14%↑

UNH

327.41

+1.82%↑

AZN

89.05

+1.79%↑

LLY

988.07

+2.29%↑

JNJ

193.84

+3.17%↑

ABBV

225.16

+3.14%↑

UNH

327.41

+1.82%↑

AZN

89.05

+1.79%↑

LLY

988.07

+2.29%↑

JNJ

193.84

+3.17%↑

ABBV

225.16

+3.14%↑

UNH

327.41

+1.82%↑

AZN

89.05

+1.79%↑

LLY

988.07

+2.29%↑

JNJ

193.84

+3.17%↑

ABBV

225.16

+3.14%↑

UNH

327.41

+1.82%↑

AZN

89.05

+1.79%↑

LLY

988.07

+2.29%↑

JNJ

193.84

+3.17%↑

ABBV

225.16

+3.14%↑

UNH

327.41

+1.82%↑

AZN

89.05

+1.79%↑

Strona główna・Stock List・Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals Inc

Closed

SectorHealthcare

537.32 9.01

Buy Sell

Overview

Share price change

24h

Current

Min

491.69

Max

543.36

Key metrics
By Trading Economics
Income	-72M -114M
Sales	74M 287M
EPS	-4.956
Profit margin	-39.75
Employees	528
EBITDA	-75M -114M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+5.61% upside

Market Stats
By TradingEconomics
Market Cap	2.1B 11B
Previous open	528.31
Previous close	537.32

News Sentiment

By Acuity

28%

72%

81 / 374 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

263.2 / 277.1 Support & Resistance

Madrigal Pharmaceuticals Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

11 lis 2025, 23:59 UTC

Earnings

Singtel's 1st Half Net Profit Surges

11 lis 2025, 22:23 UTC

Acquisitions, Mergers, Takeovers

Mineral Resources Sells Stake in Lithium Mines to Posco For $765 Million

11 lis 2025, 22:21 UTC

Earnings

Aristocrat Boosts Dividend as Annual Profit Rises 12%

11 lis 2025, 23:52 UTC

Market Talk

Gold Rises Amid Fed Rate-Cut Prospects -- Market Talk

11 lis 2025, 23:44 UTC

Earnings

Singtel's 1H Net Profit Surges

11 lis 2025, 23:42 UTC

Market Talk

Nikkei May Trade Rangebound Amid Caution over U.S. Econ Strength -- Market Talk

11 lis 2025, 23:18 UTC

Earnings

Singtel: Expects FY Operating Company EBIT to Grow Between High Single Digits and Low Double Digits Vs. Earlier Guidance of High Single-Digit Growth >Z74.SG

11 lis 2025, 23:15 UTC

Earnings

Singtel: Interim Dividend of 8.2 Singapore Cents per Share, up 17% >Z74.SG

11 lis 2025, 23:14 UTC

Earnings

Singtel 1H Underlying Net Profit S$1.35B, Up 14% >Z74.SG

11 lis 2025, 23:12 UTC

Earnings

Singtel 1H Net Exceptional Gain of S$2.05B >Z74.SG

11 lis 2025, 23:11 UTC

Earnings

Singtel 1H Net S$3.40B Vs. Net S$1.23B >Z74.SG

11 lis 2025, 23:10 UTC

Earnings

Singtel 1H Rev S$6.91B Vs. S$6.99B >Z74.SG

11 lis 2025, 23:04 UTC

Market Talk

RBA Will Sharply Focus On Australian Jobs Report -- Market Talk

11 lis 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

11 lis 2025, 21:50 UTC

Market Talk

Earnings

Health Care Roundup: Market Talk

11 lis 2025, 21:46 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Private Equity Can Benefit From 'Deal-Friendly' Antitrust Policies -- Market Talk

11 lis 2025, 21:41 UTC

Earnings

Aristocrat: Continues to Actively Pursue Strategic M&A Opportunities

11 lis 2025, 21:40 UTC

Earnings

Aristocrat: Expects to Deliver Npata Growth Over FY 2026 on a Constant Currency Basis

11 lis 2025, 21:39 UTC

Earnings

Aristocrat: Interactive Delivered Revenue Growth Mainly Due to Inclusion of NeoGames

11 lis 2025, 21:39 UTC

Earnings

Aristocrat: Key Social Casino Franchises Continued to Outperform Market

11 lis 2025, 21:39 UTC

Earnings

Aristocrat: Gaming Unit Continued to Deliver Market Share Gains

11 lis 2025, 21:38 UTC

Earnings

Aristocrat: FY Normalized Npata Up 9% in Constant Currency

11 lis 2025, 21:38 UTC

Earnings

Aristocrat: Final Dividend 49 Australian Cents/Share

11 lis 2025, 21:37 UTC

Earnings

Aristocrat: FY Statutory Net Profit from Continuing Ops A$1.18 Bln, Up 2.9%

11 lis 2025, 21:36 UTC

Earnings

Aristocrat: FY Normalized Operating Revenue A$6.3 Bln, Up 11%

11 lis 2025, 21:35 UTC

Earnings

Aristocrat: FY Normalized Npata A$1.55 Bln, Up 12.2%

11 lis 2025, 21:35 UTC

Earnings

Alcon 3Q Adj EPS 79c >ALC

11 lis 2025, 21:35 UTC

Earnings

Alcon 3Q Rev $2.61B >ALC.EB

11 lis 2025, 21:35 UTC

Earnings

Alcon Backs 2025 EPS $3.05-EPS $3.15 >ALC.EB

11 lis 2025, 21:35 UTC

Earnings

Alcon 3Q EPS 48c >ALC.EB

Peer Comparison

Price change

Madrigal Pharmaceuticals Inc Forecast

Price Target

By TipRanks

5.61% upside

12 Months Forecast

Average 523.71 USD 5.61%

High 590 USD

Low 392 USD

Based on 17 Wall Street analysts offering 12 month price targets forMadrigal Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

17 ratings

Buy

Hold

Sell

Based on 17 analysts giving stock ratings to Madrigal Pharmaceuticals Inc - Dist in the past 3 months.

Technical Score

By Trading Central

263.2 / 277.1Support & Resistance

Bearish events outweigh bullish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

81 / 374 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.